AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-11 (cancelled)

12. (new) A method for producing a human or animal plasma product or serum product comprising the following steps (a) and (b):

(a) a step of separating plasma from the whole blood originating from a human or animal and reducing leukocytes in the plasma and

(b) a step of filtering using a virus removal membrane after the step (a).

13. (new) A method for producing a human or animal plasma product or a serum product comprising the following steps (a) and (b):

(a) a step of separating plasma from the whole blood originating from a human or animal immediately after collection of the blood and reducing leukocytes in the plasma immediately after the above separation and

(b) a step of filtering using a virus removal membrane after the step (a).

14. (new) A method according to claim 12 wherein a raw material for producing the plasma product or serum product is not frozen before virus removal filtration in step (b).

15. (new) A method according to claim 12 wherein step (a) comprises separating plasma from the whole blood originating

from a human or animal within four hours from collection of the blood and reducing leukocytes in plasma immediately after said separation, and in step (b) a raw material for producing the plasma product or serum product is not frozen before virus removal filtration.

16. (new) A method according to claim 14 wherein the raw material for producing the plasma product or serum product is a plasma material.

17 (new) A method according to claim 12 wherein plasma product or serum product is a fresh frozen plasma.

18 (new) A method according to claim 13 wherein "immediately" means within four hours.

19 (new) A method according to claim 15 wherein "immediately" means within two hours.

20. (new) The method according to claim 12, wherein the virus removal membrane used in step (b) has an average pore diameter of 100 nm or less.

21. (new) The method according to claim 12, wherein the step (a) is a leukocyte-reducing step using a leukocyte removal membrane.

22. (new) The method according to claim 12, wherein the steps (a) and (b) are carried out under the condition of a temperature of 25-40°C.

23. (new) The method according to claim 12, wherein the steps (a) and (b) are carried out under the condition of a pressure of 98 kPa or less.

24. (new) The method according to claim 12, wherein the amounts of blood passing through in the steps (a) and (b) are 100-500 ml, respectively.

25. (new) The method according to claim 12, wherein the treatment time for the step (b) is 40 minutes or less.

26. (new) The method according to claim 12, wherein the virus removal membrane used in the step (b) has an average pore diameter of 75 nm or less.

27. (new) The method according to claim 12, wherein the virus removal membrane used in the step (b) is a combination of a virus removal membrane having an average pore diameter of 75 nm and another virus removal membrane having an average pore diameter of 35 nm subsequent to the former membrane.

28. (new) A human or animal plasma product or a serum product produced by a method comprising the following steps (a) and (b):
(a) a step of separating plasma from the whole blood originating from a human or animal and reducing leukocytes in the plasma and
(b) a step of filtering using a virus removal membrane after the step (a).

29. (new) A method according to claim 13 wherein a raw material for producing the plasma product or serum product is not frozen before virus removal filtration in step (□).

30. (new) A method according to claim 29 wherein the raw material for producing the plasma product or serum product is a plasma material.